Fine Organic Industries Ltd
FINEORGFine Organic Industries Ltd's earnings have outrun its stock. EPS grew +1.6% in a year against a −8.1% price move.
Biggest watch item: the price is already 11 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (11 weeks in) while the P/E sits at the 52nd percentile of its own 8-year range. Underneath, the last four quarters read improving — profit +20.6% year on year, and 102% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Fine Organic Industries Ltd trades at ₹4,817, in a confirmed uptrend and 11 weeks into that stage. That is +3.0% against its own 200-day average. It sits at 66% of a 52-week range of ₹3,887 to ₹5,286. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 11 of stage 2, confirmed. At ₹4,817 it trades +3.0% versus its 200-day average and sits at 66% of its 52-week range (₹3,887–₹5,286).
Against the market, two honest reads. Cumulative: over the last 8.1 years the stock moved +497% while the NIFTY 500 moved +151% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Fine Organic Industries Ltd trades at 36.2× P/E, mid-range by its own standards (52nd percentile). Its long-run median P/E is 36.1×, measured across 8.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 36.2× is mid-range by its own standards (52nd percentile), against a long-run median of 36.1× measured over 8.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +1.6% against a −8.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +9.9%/yr price move, ~+27.7%/yr came from earnings growth and ~−17.8 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Fine Organic Industries Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −24.5% and has held its recovery at +1.7%, ROCE slipping at 21.8%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +4.3% | −7.8% | +15.9% | +13.6% |
| Profit | +1.7% | −12.3% | +28.3% | +18.6% |
| EPS | +1.6% | −12.3% | +28.2% | −1.5% |
| Share price | −8.1% | +2.5% | +9.9% | — |
4-Factor Sector Score
43.3/100 — rank 12 of 20 in Chemicals - Organic · 96% evidence confidence
Fine Organic Industries Ltd scores 43.3 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 12. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 13.8 + 18 + 6 + 5.5 = 43.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Fine Organic Industries Ltd reported ₹625 Cr of revenue in the Mar 26 quarter, +3.0% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.6% a year. The last full year, FY26, came in at ₹2,366 Cr. The last four reported quarters add to ₹2,365 Cr.
FY26 revenue came in at ₹2,366 Cr (+4.3% on the year), capping 10 years at 13.6% compound. The latest quarter (Mar 26) printed ₹625 Cr, +3.0% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +4.4% growth against the decade's 13.6% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +4.2% over the last 4 quarters against +5.6%/yr over the last 8 — stabilising; TTM profit +1.7% vs +0.6%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Fine Organic Industries Ltd's operating margin is 21.0% in the Mar 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 17.0% to 27.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 21.0%, +1.0 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged 17.0%–27.0%.
Why the margin moved: operating margin went +0.9 pp year on year while gross margin went +0.7 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Fine Organic Industries Ltd earned ₹117 Cr of net profit in the Mar 26 quarter, +20.6% year on year. Full-year FY26 profit was ₹417 Cr. The 10-year compound rate is 18.6%. That is 18.7% of the quarter's revenue. The same quarter a year earlier earned ₹97.0 Cr.
Mar 26 profit was ₹117 Cr, +20.6% year on year. On the full year, FY26 printed ₹417 Cr (+1.7%), and the 10-year compound rate is 18.6%.
Why profit moved: revenue contributed +3.0% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +1.6% vs revenue +4.4%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 102% of Fine Organic Industries Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹430 Cr of operating cash against ₹417 Cr of profit. After ₹118 Cr of capital spending, ₹312 Cr was left as free cash.
FY26: operating cash of ₹430 Cr against reported profit of ₹417 Cr, leaving free cash of ₹312 Cr after ₹118 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 102% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 102%: the cash cycle stretched 47 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 2.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Fine Organic Industries Ltd's cash conversion cycle runs 113 days in FY26, up from 66 days in FY21. Capital spending ran ₹363 Cr over the last 3 years. At FY26 sales of ₹2,366 Cr each day of that cycle holds about ₹6.5 Cr, so roughly ₹732 Cr sits inside the business at any moment.
FY26: debtors at 54 days, inventory at 104 days — roughly 3.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 113 days, looser than FY21's 66.
The full loop: cash goes out to suppliers and production on day 0; stock waits 104 days to sell; customers pay about 54 days after that; and suppliers themselves are paid at 45 days — netting out to the 113-day cycle.
In money terms: at FY26 sales of ₹2,366 Cr, each day of the cycle holds about ₹6.5 Cr — so the 113-day loop keeps roughly ₹732 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹363 Cr over the last 3 fiscal years against ₹165 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹64.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Fine Organic Industries Ltd earns a ROCE of 21% in FY26. Return on invested capital clears the cost of that capital by +12.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 17.6% net margin on 0.79× asset turns.
FY26 ROCE is 21%.
Why the return is what it is — the wiring (FY26): 17.6% net margin × 0.79× asset turns × 1.13× balance-sheet leverage ≈ 15.7% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 24.9% − 12.0% = a +12.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Fine Organic Industries Ltd carries total debt of ₹68.0 Cr against shareholder equity of ₹2,665 Cr as of Mar 26, a debt-to-equity of 0.03 — effectively unlevered. On the annual view that ratio went from 0.06 in FY22 to 0.03 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹68.0 Cr against shareholder equity of ₹2,665 Cr — a debt-to-equity of 0.03. On the annual view, debt-to-equity went from 0.06 (FY22) to 0.03 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Fine Organic Industries Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.6 points over the same window, to 11.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.7 points over 8 quarters to 4.3%; Domestic institutions: +0.6 points over 8 quarters to 11.7%; Promoters: +0.0 points over 8 quarters to 75.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Fine Organic Industries Ltd: the Z-score reads 28.39. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 28.39 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 28.39.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nitta Gelatin India LtdKERALACHEM | 82.3/100Sector-leading setup78% evidence | 27.8/35 Revenue 11.8% · PAT 34.1% · OPM change 10 pp 83% evidence | 20.2/25 ROCE 31.3% · OPM 28% 76% evidence | 14.3/20 P/E 13.5× · PEG — 50% evidence | 20.0/20 RS sector 71.7% · RS bench 85.7% · 1Y 75.4%4 of 4 weeks ahead to 2026-06-07 100% evidence | |
| Exact sum: 27.8 + 20.2 + 14.3 + 20 = 82.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Balaji Amines LtdBALAMINES | 64.9/100Mixed-positive evidence82% evidence | LEADER | 26.7/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.2/25 ROCE 11% · OPM 25% 76% evidence | 6.6/20 P/E 33.9× · PEG — 50% evidence | 18.4/20 RS sector 27.9% · RS bench 45.8% · 1Y 26.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.2 + 6.6 + 18.4 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3OCCL LtdOCCLLTD | 62.1/100Mixed-positive evidence60% evidence | TURNING | 26.2/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.1/25 ROCE 12.8% · OPM 28% 76% evidence | 11.5/20 P/E 10.9× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 46.7% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 26.2 + 12.1 + 11.5 + 12.3 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Shri Ahimsa Naturals LtdSHRIAHIMSA | 60.8/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 17.8/25 ROCE 21.7% · OPM 28% 95% evidence | 10.3/20 P/E 30.9× · PEG — 15% evidence | 13.8/20 RS sector 22.1% · RS bench 40.5% · 1Y 114.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 17.8 + 10.3 + 13.8 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Indo Amines LtdINDOAMIN | 59.8/100Mixed-positive evidence77% evidence | TURNING | 22.5/35 Revenue 7.6% · PAT 42.9% · OPM change 2 pp 83% evidence | 16.0/25 ROCE 19.9% · OPM 11% 95% evidence | 13.9/20 P/E 11.7× · PEG — 50% evidence | 7.4/20 RS sector -12.9% · RS bench 0.5% · 1Y -15%10 of 10 weeks ahead 70% evidence |
| Exact sum: 22.5 + 16 + 13.9 + 7.4 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Foseco India LtdFOSECOIND | 57.4/100Mixed-positive evidence83% evidence | TURNING | 18.6/35 Revenue 26.9% · PAT 7.5% · OPM change 2 pp 88% evidence | 14.9/25 ROCE 17.4% · OPM 20% 100% evidence | 11.1/20 P/E 39.7× · PEG 1.31 65% evidence | 12.8/20 RS sector 22.8% · RS bench -2.4% · 1Y 5.3%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 14.9 + 11.1 + 12.8 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Elantas Beck India LtdELANTAS | 50.5/100Mixed-positive evidence72% evidence | ASLEEP | 17.2/35 Revenue 11.1% · PAT 6.6% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 21.2% · OPM 20% 76% evidence | 7.5/20 P/E 50.9× · PEG — 50% evidence | 7.9/20 RS sector -7.6% · RS bench -2.3% · 1Y -26%1 of 7 weeks ahead 70% evidence |
| Exact sum: 17.2 + 17.9 + 7.5 + 7.9 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Laxmi Organic Industries LtdLXCHEM | 48.2/100Mixed-negative evidence94% evidence | TURNING | 20.8/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.2/25 ROCE 4.7% · OPM 12% 100% evidence | 11.8/20 P/E 39.4× · PEG 1.14 100% evidence | 7.4/20 RS sector -20.5% · RS bench 6.3% · 1Y -13.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 8.2 + 11.8 + 7.4 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Valiant Organics LtdVALIANTORG | 46.9/100Mixed-negative evidence83% evidence | ASLEEP | 23.0/35 Revenue 2.6% · PAT 100% · OPM change 2 pp 83% evidence | 9.6/25 ROCE 5.5% · OPM 12% 95% evidence | 11.4/20 P/E 25.7× · PEG — 50% evidence | 2.9/20 RS sector -18.7% · RS bench -6.3% · 1Y -29.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 9.6 + 11.4 + 2.9 = 46.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -29.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Shree Ganesh Remedies LtdSGRL | 46.6/100Thin evidence · provisional57% evidence | 11.3/35 Revenue -17.3% · PAT -37.7% · OPM change -4.8 pp 53% evidence | 16.4/25 ROCE 19.2% · OPM 31.9% 57% evidence | 8.9/20 P/E 35.1× · PEG — 50% evidence | 10.0/20 RS sector 2.3% · RS bench -9.9% · 1Y -15.8%4 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 11.3 + 16.4 + 8.9 + 10 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Fairchem Organics LtdFAIRCHEMOR | 44.4/100Mixed-negative evidence87% evidence | BREAKING OUT | 18.4/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 5.7/25 ROCE 3.3% · OPM 10% 95% evidence | 6.0/20 P/E 66.4× · PEG — 50% evidence | 14.3/20 RS sector 1.2% · RS bench 16.6% · 1Y -12.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 5.7 + 6 + 14.3 = 44.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries Ltdthis pageFINEORG | 43.3/100Mixed-negative evidence96% evidence | FADING | 13.8/35 Revenue 4.2% · PAT 1.7% · OPM change 1 pp 88% evidence | 18.0/25 ROCE 21.5% · OPM 21% 100% evidence | 6.0/20 P/E 36.2× · PEG 2.7 100% evidence | 5.5/20 RS sector -10.6% · RS bench 3.4% · 1Y -7.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 18 + 6 + 5.5 = 43.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13GFL LtdGFLLIMITED | 43.0/100Mixed-negative evidence62% evidence | 20.6/35 Revenue 0% · PAT 100% · OPM change 2562 pp 62% evidence | 6.3/25 ROCE 2.1% · OPM 19% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 4.8/20 RS sector -14.7% · RS bench -16.8% · 1Y -28.6%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 6.3 + 11.3 + 4.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14BASF India LtdBASF | 40.7/100Mixed-negative evidence90% evidence | ASLEEP | 11.9/35 Revenue -0.4% · PAT -12.5% · OPM change 1.7 pp 88% evidence | 9.3/25 ROCE 14.5% · OPM 3.2% 100% evidence | 12.2/20 P/E 38.1× · PEG 1.62 100% evidence | 7.3/20 RS sector -4.4% · RS bench -8.7% · 1Y -28%1 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 9.3 + 12.2 + 7.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Oriental Aromatics LtdOAL | 38.5/100Mixed-negative evidence74% evidence | TURNING | 13.0/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 7.2/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 231× · PEG — 15% evidence | 9.6/20 RS sector -9.8% · RS bench 15.9% · 1Y -3.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 7.2 + 8.7 + 9.6 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Gem Aromatics LtdGEMAROMA | 31.4/100Thin evidence · provisional56% evidence | TURNING | 4.3/35 Revenue -27.3% · PAT -80% · OPM change -8.4 pp 83% evidence | 8.6/25 ROCE 3.4% · OPM 14.2% 95% evidence | 8.5/20 P/E 705× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 4.3 + 8.6 + 8.5 + 10 = 31.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sigachi Industries LtdSIGACHI | 25.4/100Adverse evidence77% evidence | TURNING | 6.2/35 Revenue -2.1% · PAT -80% · OPM change -8.8 pp 83% evidence | 6.9/25 ROCE 6.2% · OPM 13.5% 95% evidence | 8.5/20 P/E 30.4× · PEG — 50% evidence | 3.8/20 RS sector -35.5% · RS bench -8.5% · 1Y -33.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 6.9 + 8.5 + 3.8 = 25.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Sacheerome LtdSACHEEROME | 59.9/100Thin evidence · provisional41% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.6/25 ROCE 35.7% · OPM 23% 95% evidence | 10.2/20 P/E 33.3× · PEG — 15% evidence | 11.7/20 RS sector — · RS bench 30.9% · 1Y 141.7%3 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 20.6 + 10.2 + 11.7 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Jyoti Resins and Adhesives LtdJYOTIRES | 46.1/100Thin evidence · provisional50% evidence | 13.2/35 Revenue 8.7% · PAT -5.5% · OPM change -6 pp 53% evidence | 18.7/25 ROCE 50% · OPM 26% 57% evidence | 10.8/20 P/E 14.3× · PEG — 15% evidence | 3.4/20 RS sector -20.6% · RS bench -30.3% · 1Y -40.3%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 13.2 + 18.7 + 10.8 + 3.4 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 41.1/100Thin evidence · provisional18% evidence | 14.3/35 Revenue — · PAT -30.4% · OPM change — 18% evidence | 6.8/25 ROCE -2150% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 14.3 + 6.8 + 10 + 10 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Fine Organic Industries Ltd's share price today?
Fine Organic Industries Ltd trades at ₹4,817, −8.1% over the past year. The company is valued at ₹14,767 Cr. The stock sits at 66% of its 52-week range of ₹3,887–₹5,286, +3.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 11 weeks in. — as of 31 July 2026.
What were Fine Organic Industries Ltd's latest quarterly results?
Fine Organic Industries Ltd reported revenue of ₹625 Cr and net profit of ₹117 Cr for the Mar 26 quarter. Revenue rose 3.0% and profit rose 20.6% year on year. Earnings per share were ₹38.32. The operating margin was 21.0%, 1.0 pp higher than a year earlier. — as of 31 July 2026.
What is Fine Organic Industries Ltd's revenue?
Fine Organic Industries Ltd reported revenue of ₹625 Cr in the Mar 26 quarter, +3.0% year on year. For the full FY26 fiscal year, revenue was ₹2,366 Cr (+4.3%). Over the last 10 years revenue compounded at 13.6% a year. — as of 31 July 2026.
What is Fine Organic Industries Ltd's profit?
Fine Organic Industries Ltd earned ₹117 Cr of net profit in the Mar 26 quarter, +20.6% year on year. Full-year FY26 profit was ₹417 Cr. The operating margin ran 21.0% in the latest quarter. — as of 31 July 2026.
What is Fine Organic Industries Ltd's market cap?
Fine Organic Industries Ltd's market capitalisation is ₹14,767 Cr at a share price of ₹4,817. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Fine Organic Industries Ltd's P/E ratio?
Fine Organic Industries Ltd trades at a P/E of 36.2×, at the 52nd percentile of its own 8-year range, against a long-run median of 36.1×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Fine Organic Industries Ltd pay a dividend?
Yes — Fine Organic Industries Ltd's dividend payout was 8% of profit in FY26, and it recorded a payout in each of its last 11 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Fine Organic Industries Ltd overvalued?
On its own history, Fine Organic Industries Ltd looks mid-range against its own history: its P/E of 36.2× sits at the 52nd percentile of its 8-year range (long-run median 36.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Fine Organic Industries Ltd growing?
Yes — Fine Organic Industries Ltd is growing: latest-quarter revenue +3.0% year on year, profit +20.6%, and the margin +1.0 pp at 21.0%. The 10-year compound rates are 13.6% (revenue) and 18.6% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Fine Organic Industries Ltd performing?
Fine Organic Industries Ltd is in a confirmed uptrend, 11 weeks in. Its latest quarter's revenue rose 3.0% and profit rose 20.6% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Fine Organic Industries Ltd in?
Improving — profit growth bottomed 8 quarters ago at −24.5% and has held its recovery at +1.7%, ROCE slipping at 21.8%. The read comes from the last 12 quarters of growth (revenue growth +4.2% latest, profit growth +1.7% latest, eps growth +1.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Fine Organic Industries Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 11 of stage 2), trading +3.0% versus its 200-day average and at 66% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Fine Organic Industries Ltd beating the market?
Not lately — on a trailing-13-week view Fine Organic Industries Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.1 years the stock moved +497% against the NIFTY 500's +151% — ahead of the index over the full window. — as of 31 July 2026.
Will Fine Organic Industries Ltd's share price go up?
This page publishes no price forecast for Fine Organic Industries Ltd. What it measures instead: the share price is ₹4,817, the price is in a confirmed uptrend 11 weeks in. Its P/E of 36.2× sits at the 52nd percentile of its own 8-year range. — as of 31 July 2026.
Who owns Fine Organic Industries Ltd?
Promoters hold 75.0% of Fine Organic Industries Ltd, foreign institutions 4.3%, domestic institutions 11.7% and the public 9.0% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Fine Organic Industries Ltd have too much debt?
No — Fine Organic Industries Ltd's debt-to-equity is 0.03, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹68.0 Cr against equity of ₹2,664 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Fine Organic Industries Ltd's capex?
Fine Organic Industries Ltd spent ₹363 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹118 Cr, with ₹64.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Fine Organic Industries Ltd's cash flow?
Fine Organic Industries Ltd generated ₹430 Cr of operating cash flow in FY26 and ₹312 Cr of free cash flow after ₹118 Cr of capital spending. Reported profit that year was ₹417 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Fine Organic Industries Ltd's profit real cash?
Yes — over the last 3 fiscal years, 102% of Fine Organic Industries Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹430 Cr against reported profit of ₹417 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
How financially safe is Fine Organic Industries Ltd?
On the balance sheet, the Z-score reads 28.39 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 31 July 2026.
Where is Fine Organic Industries Ltd in its business cycle?
Fine Organic Industries Ltd's FY26 operating margin was 20.0%, against a 11-year band of 17.0%–27.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Fine Organic Industries Ltd story?
Biggest watch item: the price is already 11 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Fine Organic Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Fine Organic Industries Ltd's earnings have outrun its stock. EPS grew +1.6% in a year against a −8.1% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.